Edward V Nunes Jr. MD

Psychiatry•New York, NY

Addiction

Professor, Psychiatry, Columbia University College of Phys & Surg

Join to View Full Profile

617 W End AveSte 1BNew York, NY 10024
Phone+1 212-579-0339
Fax+1 212-202-4187

Education & Training

New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1985 - 1988
New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1982 - 1985
St Elizabeth's Medical CenterInternship, Internal Medicine, 1981 - 1982
Uconn School Of MedicineClass of 1981

Certifications & Licensure

NY State Medical License 1983 - 2025
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Addiction Psychiatry
American Board of Preventive Medicine Addiction Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2008-2009, 2013-2014

Clinical Trials

Early Phase II Trials for Cocaine Medication Development - 1 Start of enrollment: 1996 Aug 01
Completed
Phase 2
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Start of enrollment: 1999 Aug 01
Completed
Phase 2
Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence Start of enrollment: 2002 Jun 01
Completed
Phase 2
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Start of enrollment: 2007 Sep 01
Completed
Phase 3
Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site Start of enrollment: 2008 Jun 01
Completed
Phase 2, Phase 3
Training Clinicians in Motivational Interviewing Start of enrollment: 2010 Mar 01
Completed
Not Applicable
Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders Start of enrollment: 2010 Apr 01
Completed
Not Applicable
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Start of enrollment: 2017 May 05
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.
Matisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, Martina Pavlicova, John Rotrosen
Drug and Alcohol Dependence. 2025-03-01
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).
Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, Scott Provost, Kaitlyn Ohrtman
Contemporary Clinical Trials. 2025-03-01
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.
Ignacio Bórquez, Arthur R Williams, Mei-Chen Hu, Marc Scott, Maureen T Stewart
Addiction. 2025-02-26

Journal Articles

Bupropion and Naltrexone in Methamphetamine Use Disorder
Madhukar H Trivedi, Gavin Bart, Edward V Nunes, Steven Shoptaw, The New England Journal of Medicine
Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse
Joshua D Lee, John Rotrosen, Edward V Nunes, Annals of Internal Medicine
American Psychiatric Association Publishing
Adam Bisaga, Frances R Levin, John J Mariani, Maria A Sullivan, Edward V Nunes, National Institutes of Health

Press Mentions

Workshop on Implementation Science and Digital Therapeutics for Behavioral HealthJanuary 28th, 2021
Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-Line Phase 3 Results for Long-Acting Buprenorphine for Treatment of Opioid AddictionNovember 14th, 2016
Treatment for Cocaine DependenceDecember 3rd, 2014
Join now to see all

Grant Support

Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery EnhancementUNIVERSITY OF UTAH2024–2026
CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York StateCOLUMBIA UNIV NEW YORK MORNINGSIDE2019–2025
Facilitating Opioid Care Connections: System level strategies to improve use of MAT and movement through the opioid care cascade for defendants in a new Opioid Court systemNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2019–2025
Evaluation of safety and pharmacokinetics of naltrexone implantNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2018–2025
NIDA Clinical Trials Network: New York NodeNEW YORK UNIVERSITY SCHOOL OF MEDICINE2001–2025
Training Motivational Interviewing Using Live SupervisionNational Institute On Drug Abuse2010–2012
Clinical Trials Network: Greater New York NodeNational Institute On Drug Abuse2010–2012
Treatment Studies Using Depot Naltrexone (4/6) Columbia Protocol Treatment SiteNational Institute On Drug Abuse2008–2012
Drug Abuse Treatment Development And Research MentoringNational Institute On Drug Abuse2007–2011
Clinical Trials Network: Long Island Regional NodeNational Institute On Drug Abuse2007–2010
New Approaches To Cocaine Abuse MedicationsNational Institute On Drug Abuse1997–2008
Cu Partners: Ny/Long Island Regional NodeNational Institute On Drug Abuse2001–2007
MI Training: Live Supervision By Tele-ConferenceNational Institute On Drug Abuse2003–2006
Opiate Dependence: Combined Naltrexone/Behavior TherapyNational Institute On Drug Abuse2000–2006
Drug Abuse Pharmacotherapy: Methodologic InitiativesNational Institute On Drug Abuse2001–2005
Excitatory And Inhibitory Pathways For Cocaine TreatmentNational Institute On Drug Abuse1999–2002
Behavioral Therapy For Depression In Drug DependenceNational Institute On Drug Abuse1999–2002
Drug Abuse Pharmacotherapy--Methodolgic InitiativesNational Institute On Drug Abuse1996–2000
Early Phase II Trials For Cocaine Medication DevelopmentNational Institute On Drug Abuse1995–1998
Sertraline Treatment Of Depressed Methadone PatientsNational Institute On Drug Abuse1994–1997
Drug Abuse Treatment Comorbidity And Clinical TrialsNational Institute On Drug Abuse1995
Drug Abuse Treatment Comorbidity And Clinical TrialsNational Institute On Drug Abuse1991–1994